{"scopus-eid": "2-s2.0-85144796715", "originalText": "serial JL 273258 291210 291681 291808 291847 31 90 Acta Biomaterialia ACTABIOMATERIALIA 2022-12-10 2022-12-10 2023-01-26 2023-01-26 2023-01-26T03:58:23 1-s2.0-S1742706122008066 S1742-7061(22)00806-6 S1742706122008066 10.1016/j.actbio.2022.12.004 S300 S300.1 FULL-TEXT 1-s2.0-S1742706123X00026 2023-02-10T05:24:01.239563Z 0 0 20230201 20230228 2023 2022-12-10T01:00:00.223971Z absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid fundingbodyid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight oauserlicense openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sortorder sponsoredaccesstype srctitle srctitlenorm srctype ssids alllist content oa subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body mmlmath acknowledge affil articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid primabst pubtype ref specialabst 1742-7061 17427061 UNLIMITED NONE true 157 157 C Volume 157 25 337 351 337 351 202302 February 2023 2023-02-01 2023-02-28 2023 article fla \u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc. IDARUBICINLOADEDBIODEGRADABLEMICROSPHERESENHANCESENSITIVITYANTIPD1IMMUNOTHERAPYINTRANSCATHETERARTERIALCHEMOEMBOLIZATIONHEPATOCELLULARCARCINOMA ZHENG Z 1 Introduction 2 Materials and methods 2.1 Preparation of BILMs 2.2 IDA loading efficiency 2.3 Morphology, size, and distribution 2.4 The release of IDA in vitro 2.5 Cell cultures 2.6 Preparation of preclinical rabbit liver tumor model 2.7 Rabbit liver tumor model grouping and drug delivery 2.8 In vivo tumor mice model and treatment 2.9 Hematoxylin-eosin (HE) and immunohistochemistry 2.10 Mass cytometry 2.11 Statistical analysis 3 Results 3.1 The loading efficiency of IDA 3.2 Morphology, size, and distribution of BILMs 3.3 The release of IDA in vitro 3.4 TACE with IDA-MS significantly inhibited tumor growth in rabbit VX2 HCC model 3.5 TACE with IDA-MS reduced tumor growth and increased the efficiency of anti-PD1 treatment in mice HCC model 3.6 Changes of tumor immune microenvironment after IDA-MS treatment in HCC mice model based on mass cytometry 4 Discussion 5 Conclusion Funding Details of authors' contributions Acknowledgments References TRESKA 2020 2919 2925 V COLLIN 2019 42 47 Y MADOFF 2020 59 D CHAKRABORTY 2022 2798 E WILLATT 2015 235 244 J GABA 2016 752 761 R VANBREUGEL 2019 3674 3686 J LLOVET 2003 429 442 J MA 2014 736 744 W LONGO 2017 33897 33910 V GBOLAHAN 2017 215 228 O MIKHAIL 2022 121466 A LI 2019 1849 1861 H BOURCIER 2022 114543 B LEWIS 2018 2741 2760 A MIKHAIL 2022 495 501 A NEGUSSIE 2021 533 A DURAN 2016 28 39 R ASHRAFI 2017 36 47 K LIU 2015 212 219 Y OKAMOTO 2020 109106 Y POURSAID 2016 414 433 A JAFARI 2022 119045 A MIHAILA 2013 895 907 S RODE 2018 422 434 M BAKARICH 2014 38088 38092 S KUNLIANG 2020 866 878 L GOLUNSKI 2016 118 125 G GUIU 2019 1303 1309 B GUIU 2019 801 808 B DELICQUE 2018 2761 2772 J VERRET 2014 1759 1766 V JEON 2022 409 425 S GONZALEZ 2008 767 775 M SONG 2012 1244 1250 M BOULIN 2014 1301 1313 M ZHOU 2018 644 G BOULIN 2016 601 609 M BOULIN 2011 741 748 M ROTH 2020 324 334 G DURAN 2019 695 703 R QIAN 2021 2933 2946 Y CHIANG 2018 3425 3433 P DENYS 2017 2164 2176 A SAKR 2016 199 207 O ZAMORANO 2016 2768 2801 J LENCIONI 2016 1090 1098 R BORDE 2020 1706 1716 T FAVELIER 2013 1039 1046 S GUIU 2018 1163 1171 B ELKHOUEIRY 2017 2492 2502 A QIN 2020 571 580 S FINN 2020 1894 1905 R HERBST 2014 563 567 R ZHENGX2023X337 ZHENGX2023X337X351 ZHENGX2023X337XZ ZHENGX2023X337X351XZ Full 2022-12-07T14:59:48Z Author http://creativecommons.org/licenses/by-nc-nd/4.0/ 2025-01-26T00:00:00.000Z 2025-01-26T00:00:00.000Z http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license. \u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc. 2023-02-10T05:21:59.559Z http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined National Natural Science Foundation of China 82073804 NSFC National Natural Science Foundation of China http://data.elsevier.com/vocabulary/SciValFunders/501100001809 http://sws.geonames.org/1814991/ National Key Research and Development Program of China 2017YFA0205501 NKRDPC National Key Research and Development Program of China http://data.elsevier.com/vocabulary/SciValFunders/501100012166 http://sws.geonames.org/1814991/ This work was supported by the grants from National Key Research and Development Program of China (Grant No.2017YFA0205501), the National Natural Science Foundation of China (Grant No. 82073804 ). item S1742-7061(22)00806-6 S1742706122008066 1-s2.0-S1742706122008066 10.1016/j.actbio.2022.12.004 273258 2023-02-01T00:46:21.339461Z 2023-02-01 2023-02-28 UNLIMITED NONE 1-s2.0-S1742706122008066-main.pdf https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/MAIN/application/pdf/cb185bfc508de2649a9771231e871ff3/main.pdf main.pdf pdf true 7394000 MAIN 15 1-s2.0-S1742706122008066-main_1.png https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/PREVIEW/image/png/808f11f3935d01d43a188b8528d650bf/main_1.png main_1.png png 56006 849 656 IMAGE-WEB-PDF 1 1-s2.0-S1742706122008066-gr1.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr1/DOWNSAMPLED/image/jpeg/9a1a22d04b0694a7f9682accb9ec7aca/gr1.jpg gr1 gr1.jpg jpg 73106 907 565 IMAGE-DOWNSAMPLED 1-s2.0-S1742706122008066-gr2.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr2/DOWNSAMPLED/image/jpeg/5d4d6889e3fe42b04c202bc00b563ead/gr2.jpg gr2 gr2.jpg jpg 114154 941 565 IMAGE-DOWNSAMPLED 1-s2.0-S1742706122008066-gr3.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr3/DOWNSAMPLED/image/jpeg/cd1e608f7971f00b808cf69ff0bb8bf4/gr3.jpg gr3 gr3.jpg jpg 253017 969 602 IMAGE-DOWNSAMPLED 1-s2.0-S1742706122008066-gr4.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr4/DOWNSAMPLED/image/jpeg/228cd96e1474674c7874778fc7e1f8d9/gr4.jpg gr4 gr4.jpg jpg 118799 913 640 IMAGE-DOWNSAMPLED 1-s2.0-S1742706122008066-gr5.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr5/DOWNSAMPLED/image/jpeg/cf1831554014009367941115ff3da682/gr5.jpg gr5 gr5.jpg jpg 296693 940 572 IMAGE-DOWNSAMPLED 1-s2.0-S1742706122008066-gr6.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr6/DOWNSAMPLED/image/jpeg/6487b9b178c6848502338a4e8c8589e5/gr6.jpg gr6 gr6.jpg jpg 223284 987 621 IMAGE-DOWNSAMPLED 1-s2.0-S1742706122008066-gr7.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr7/DOWNSAMPLED/image/jpeg/f75a0419d5e666a6454bc8330c7c20bc/gr7.jpg gr7 gr7.jpg jpg 236681 941 534 IMAGE-DOWNSAMPLED 1-s2.0-S1742706122008066-gr8.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr8/DOWNSAMPLED/image/jpeg/a4d5416814c077cd357f3d27d1aef3bb/gr8.jpg gr8 gr8.jpg jpg 130310 993 378 IMAGE-DOWNSAMPLED 1-s2.0-S1742706122008066-ga1.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/ga1/DOWNSAMPLED/image/jpeg/b4224a05e73b475f56c0d95fb8517caa/ga1.jpg ga1 true ga1.jpg jpg 27399 200 274 IMAGE-DOWNSAMPLED 1-s2.0-S1742706122008066-gr1.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr1/THUMBNAIL/image/gif/b8ee5d952dc4f801f738bf5dd70db455/gr1.sml gr1 gr1.sml sml 5048 164 102 IMAGE-THUMBNAIL 1-s2.0-S1742706122008066-gr2.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr2/THUMBNAIL/image/gif/8c675425eb5679f2630c04886272163b/gr2.sml gr2 gr2.sml sml 8543 163 98 IMAGE-THUMBNAIL 1-s2.0-S1742706122008066-gr3.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr3/THUMBNAIL/image/gif/dec814e1207369983582abe9ed293daf/gr3.sml gr3 gr3.sml sml 12484 163 101 IMAGE-THUMBNAIL 1-s2.0-S1742706122008066-gr4.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr4/THUMBNAIL/image/gif/8024fff4bf4c9b832e81ab6f18084f44/gr4.sml gr4 gr4.sml sml 7980 164 115 IMAGE-THUMBNAIL 1-s2.0-S1742706122008066-gr5.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr5/DOWNSAMPLED/image/gif/07dc1e83d66c01cdaa7032bf42006ccc/gr5.sml gr5 gr5.sml sml 12188 163 99 IMAGE-THUMBNAIL 1-s2.0-S1742706122008066-gr6.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr6/THUMBNAIL/image/gif/09663a1999713be30287f35628a4ca52/gr6.sml gr6 gr6.sml sml 8959 164 103 IMAGE-THUMBNAIL 1-s2.0-S1742706122008066-gr7.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr7/THUMBNAIL/image/gif/b0c9c5d2efecdd70778c83d6e6d29961/gr7.sml gr7 gr7.sml sml 11631 164 93 IMAGE-THUMBNAIL 1-s2.0-S1742706122008066-gr8.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/gr8/THUMBNAIL/image/gif/f1c81ec2814cd4f0c39e8adf9c81597d/gr8.sml gr8 gr8.sml sml 5724 163 62 IMAGE-THUMBNAIL 1-s2.0-S1742706122008066-ga1.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/ga1/THUMBNAIL/image/gif/c68f0645f692db5001e9ac148bf29c99/ga1.sml ga1 true ga1.sml sml 15085 160 219 IMAGE-THUMBNAIL 1-s2.0-S1742706122008066-gr1_lrg.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/DOWNSAMPLED/image/jpeg/4bc3224dadb1d4b097954017e06dd66b/gr1_lrg.jpg gr1 gr1_lrg.jpg jpg 547381 4015 2500 IMAGE-HIGH-RES 1-s2.0-S1742706122008066-gr2_lrg.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/MAIN/image/jpeg/6c23a60084ea7feccb66eda8e5315b00/gr2_lrg.jpg gr2 gr2_lrg.jpg jpg 924932 4164 2500 IMAGE-HIGH-RES 1-s2.0-S1742706122008066-gr3_lrg.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/HIGHRES/image/jpeg/9de20456c354061adcca3184b5f26fdb/gr3_lrg.jpg gr3 gr3_lrg.jpg jpg 2386002 4295 2667 IMAGE-HIGH-RES 1-s2.0-S1742706122008066-gr4_lrg.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/HIGHRES/image/jpeg/225031a6cb53b15571cc33d137d0d1dd/gr4_lrg.jpg gr4 gr4_lrg.jpg jpg 938992 4040 2833 IMAGE-HIGH-RES 1-s2.0-S1742706122008066-gr5_lrg.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/HIGHRES/image/jpeg/59f8c64c007904f2e63b7e7c2aa87377/gr5_lrg.jpg gr5 gr5_lrg.jpg jpg 3126291 4165 2534 IMAGE-HIGH-RES 1-s2.0-S1742706122008066-gr6_lrg.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/HIGHRES/image/jpeg/4f7d476522835118b7e98bff1cbad99b/gr6_lrg.jpg gr6 gr6_lrg.jpg jpg 2102340 4372 2750 IMAGE-HIGH-RES 1-s2.0-S1742706122008066-gr7_lrg.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/DOWNSAMPLED/image/jpeg/2ac67b8340a2cae97f606cdbaafe1920/gr7_lrg.jpg gr7 gr7_lrg.jpg jpg 2734602 4167 2365 IMAGE-HIGH-RES 1-s2.0-S1742706122008066-gr8_lrg.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/HIGHRES/image/jpeg/91a3544403119bc1beb4f39c6403ed6d/gr8_lrg.jpg gr8 gr8_lrg.jpg jpg 1288439 4398 1675 IMAGE-HIGH-RES 1-s2.0-S1742706122008066-ga1_lrg.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/HIGHRES/image/jpeg/e88f1907e28bb1d20fd32899c452ede0/ga1_lrg.jpg ga1 true ga1_lrg.jpg jpg 204816 886 1215 IMAGE-HIGH-RES 1-s2.0-S1742706122008066-si1.svg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/STRIPIN/image/svg+xml/62beb051ab1aff798fd01b4737dc9772/si1.svg si1 si1.svg svg 7895 ALTIMG 1-s2.0-S1742706122008066-si2.svg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/STRIPIN/image/svg+xml/e6c3ca64adb84b7460bedafe853fd23d/si2.svg si2 si2.svg svg 6991 ALTIMG 1-s2.0-S1742706122008066-si6.svg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/STRIPIN/image/svg+xml/08be28842b711174931c7bd06f6a8846/si6.svg si6 si6.svg svg 18461 ALTIMG 1-s2.0-S1742706122008066-si3.svg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/STRIPIN/image/svg+xml/71637d9d1555738029fab6741bcd9c39/si3.svg si3 si3.svg svg 26294 ALTIMG 1-s2.0-S1742706122008066-si4.svg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/STRIPIN/image/svg+xml/de674ddc19dd254a624c26f23f14ff97/si4.svg si4 si4.svg svg 23912 ALTIMG 1-s2.0-S1742706122008066-si5.svg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1742706122008066/STRIPIN/image/svg+xml/319e266af5acdefdad338d982e17ccbe/si5.svg si5 si5.svg svg 36625 ALTIMG 1-s2.0-S1742706122008066-am.pdf am am.pdf pdf 4946231 AAM-PDF https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10NFRCZMDQ0/MAIN/application/pdf/61c6006c40f9c193cf42a8b083ef5693/am.pdf ACTBIO 8463 S1742-7061(22)00806-6 10.1016/j.actbio.2022.12.004 Fig. 1 IDA Loading efficiency, morphology and release of IDA in vitro. (A) Standard curve of the concentration of idarubicin in water and the OD at 490 nm. The function is y = 0.009281 \u00d7 x \u2212 0.007095 .(B) IDA Loading efficiency of BILMs(n = 3). The ratio of IDA to BILMs is 5 mg/ml.(C) The morphology of BILMs before(a) and after(b) loaded with IDA. (D)Diameter distribution of BILMs before(a) and after(b) loaded with IDA. Random 200 microspheres were counted in each group. (E) Standard curve of the concentration of idarubicin in 0.9% NaCl solution and the OD at 490 nm. The function is y = 0.008784 \u00d7 x \u2212 0.003104 . (F) Cumulative release of IDA in 0.9% NaCl saline solution. Fig 1 Fig. 2 The results of DSA and PET-CT after TACE with IDA-MS or IDA in VX2 rabbit liver model. (A) Real-time DSA of pre- and post-embolizing in IDA and IDA-MS group. (B) Transverse section in PET-CT images before TACE and 7 days after TACE in IDA and IDA-MS group. Fig 2 Fig. 3 The results of PET-CT and HE staining after TACE with IDA-MS or IDA in VX2 rabbit liver model. (A) Coronal section median sagittal section and metabolic region of rabbits\u2019 PET-CT images before TACE and 7 days after TACE in IDA and IDA-MS group. (B) Overview of organ tumor and HE staining picture of respective organs or tissues. Scale bar: 25 \u00b5m. Fig 3 Fig. 4 IDA-MS reduced tumor growth and increased the efficiency of anti-PD1 in H22 tumor model. (A)Experimental design. (B)Photographs of excised tumors in each group (IDA, IDA-MS, IDA+\u03b1PD1, and IDA-MS+\u03b1PD1). (C-D) The volume (C) and weight (D) statistics of subcutaneous tumors in the respective group. (E) PET images for each group of tumor-bearing rats. (F) Fold change of max ID%/g. Fig 4 Fig. 5 HE and immunohistochemical results after TACE with IDA-MS or IDA in H22 tumor model. (A)Immunohistochemistry of tumor sections in each group. The morphology of subcutaneous tumors in four groups was confirmed by HE staining. Moreover, the upper panel also indicates immunohistochemical results of Ki67, TUNEL, PD-L1, CD3, and CD8 expression in each group. Scale bar: 25 \u00b5m (B) The results of corresponding indicator statistics in four groups. **P < 0.01 vs IDA group; ***P < 0.001 vs IDA group +P < 0.05 vs IDA-MS group; ++P < 0.01 vs IDA-MS group ^P < 0.05 vs IDA-MS+\u03b1PD1 group; ^^P < 0.01 vs IDA-MS+\u03b1PD1 group. Fig 5 Fig. 6 Mass cytometry reflected the immune microenvironment of subcutaneous H22 tumors after IDA/IDA-MS treatment. (A)Distribution of CD45+ cells by TSNE plot. (B)The ratio of CD45+ cells in the IDA and IDA-MS group respectively. (C)A total of 29 cell clusters were divided, and we defined the respective group. (D)TSNE plot showing distributions of 29 cell clusters and the TSNE diagram showing the distribution of cell clusters in the respective sample. (E)The histogram showing the number of the respective cell cluster in different groups by mass cytometry. Fig 6 Fig. 7 The expression of cell clustering marker genes via mass cytometry. TSNE as a form of presentation. Fig 7 Fig. 8 Mass cytometry reflected the marker expression changes after IDA/IDA-MS treatment. (A-D) TSNE plot showing the distribution of PD1, PD-L1, IFN-g and TNF-a in subcutaneous H22 tumors in the IDA and IDA-MS groups. (E) The histogram showing the number of PD1+ cells, PD-L1+ cells, IFN-g+ cells, and TNF-a+ cells cluster in IDA and IDA-MS groups. Fig 8 Table 1 Summary of IDA-loaded microspheres. Table 1 Trade names Material Diameter(\u00b5m) Loading times (5 mg of IDA per 1 ml of microsphere) \u2020 Absorbable(Y/N) BILMs Carrageenan and gelatin 30\u20131200 27 5min Yes DC Bead\u2122 Polyvinyl alcohol-co-Poly(2-acrylamido-2-methylpropane sulfonate) 22 70\u2013500 15 min 28 No CalliSphere\u00ae Chemical modified polyvinyl alcohol (PVA) 100\u20131200 10 min 29 No HepaSphere\u2122 Polyvinyl acetate-co-polymethylacrylate 22 30\u2013100 30 min 28 No TANDEM \u00ae Sodium methacrylate hydrogel 31 40, 75, 100 15 min 28 No LifePearl\u2122 Copolymer of polyethylene glycol diacrylamide 100\u2013400 15 min 28 Unknown \u2020 The loading efficiency should be above 95%. Full length article Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma Zhiying Zheng a b 1 Mingxi Ma c 1 Xiuping Han d 1 Xiao Li e 1 Jinxin Huang c Yuetong Zhao d Hanyuan Liu e Junwei Kang b Xiangyi Kong a Guoqiang Sun e Guangshun Sun e Jie Kong f \u204e Weiwei Tang a \u204e Guoqiang Shao d \u204e Fei Xiong c \u204e Jinhua Song a \u204e a Hepatobiliary Center, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China Hepatobiliary Center Key Laboratory of Liver Transplantation Chinese Academy of Medical Sciences NHC Key Laboratory of Living Donor Liver Transplantation The First Affiliated Hospital of Nanjing Medical University Nanjing China aHepatobiliary Center, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China b Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China Department of Anesthesiology and Perioperative Medicine The First Affiliated Hospital of Nanjing Medical University Nanjing China bDepartment of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China c State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering & Collaborative Innovation Center of Suzhou Nano-Science and Technology, Southeast University, Nanjing, China State Key Laboratory of Bioelectronics Jiangsu Key Laboratory for Biomaterials and Devices School of Biological Science and Medical Engineering & Collaborative Innovation Center of Suzhou Nano-Science and Technology Southeast University Nanjing China cState Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering & Collaborative Innovation Center of Suzhou Nano-Science and Technology, Southeast University, Nanjing, China d Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China Department of Nuclear Medicine Nanjing First Hospital Nanjing Medical University Nanjing China dDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China e Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China Department of General Surgery Nanjing First Hospital Nanjing Medical University Nanjing China eDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China f Department of Intervention, Nanjing First Hospital, Nanjing Medical University, Nanjing, China Department of Intervention Nanjing First Hospital Nanjing Medical University Nanjing China fDepartment of Intervention, Nanjing First Hospital, Nanjing Medical University, Nanjing, China \u204e Corresponding authors. 1 Indicates all are first authors Transarterial chemoembolization (TACE) is an image-guided locoregional therapy used for the treatment of patients with primary hepatocellular carcinoma (HCC). However, conventional TACE formulations such as epirubicin-lipiodol emulsion are rapidly dissociated due to the instability of the emulsion, resulting in insufficient local drug concentrations in the target tumor. To overcome these limitations, we used biodegradable Idarubicin loaded microspheres (BILMs), which were prepared from gelatin and carrageenan and could be loaded with Idarubicin (IDA-MS). The morphology and the ability to load and release IDA of BILMs were characterized in vitro. We evaluated tumor changes and side effects after TACE treatment with IDA-MS in VX2 rabbit and C57BL/6 mice HCC models. In addition, the effect of IDA-MS on the tumor immune microenvironment of HCC tumors was elucidated via mass spectrometry and immunohistochemistry. Result showed that IDA-MS was developed as a new TACE formulation to overcome the poor delivery of drugs due to rapid elimination of the anticancer drug into the systemic circulation. We demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment. Statement of significance Conventional transarterial chemoembolization (TACE) formulations are rapidly dissociated due to the instability of the emulsion, resulting in insufficient local drug concentrations in hepatocellular carcinoma (HCC). To overcome these limitations, we used biodegradable microspheres called BILMs, which could be loaded with Idarubicin (IDA-MS). We demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment. Graphical abstract Image, graphical abstract Keywords Idarubicin Hepatocellular carcinoma Transcatheter arterial chemoembolization Biodegradable microspheres Immune PD-L1 PD1 1 Introduction Liver cancer is a malignant tumor arising from hepatocytes or intrahepatic bile duct epithelial cells, with insidious onset, rapid progression and poor prognosis [1]. According to the latest statistics, in 2020, there will be 748,300 new cases of liver cancer and 695,900 deaths from liver cancer worldwide [2]. Half of these new cases and deaths occurred in China, which has one of the highest rates of liver cancer in East Asia [3]. When diagnosed early and when the tumor is <5 cm in size, liver transplantation and surgical resection are the treatment option for hepatocellular carcinoma (HCC), as the most common liver cancer. However, a majority of the patients present at advanced stages because the disease is mostly asymptomatic in early stages [4]. Image-guided intra-arterial therapy, such as transarterial chemoembolization (TACE), is a valuable tool in the treatment of primary HCC [5]. The infusion emulsion such as epirubicin-lipiodol emulsion delivers anticancer drugs directly to the tumor and blocks terminal arterioles with lipiodol [6,7]. However, the clinical outcomes of TACE remain unsatisfactory, typically causing a partial response in only 15\u201355% of patients and increasing median survival from 16 to 20 months [8,9]. During TACE surgery, due to the instability of the emulsion, a considerable part of chemotherapy drugs enter the systemic circulation, resulting in low administration efficiency and systemic side effects. Therefore, the establishment of a new TACE drug delivery system that facilitates drug delivery is crucial to enhance tumor control and reduce the side effects of HCC. Cancer cells including HCC are capable of evading immune surveillance, facilitating cancer development via activating diverse immunity checkpoint signal paths. Monoclonal antibodies that target immunity checkpoints have witnessed a huge breakthrough in tumor treatment, promoting the immunity-mediated eradication of oncocytes. Amongst those, programmed death-ligand 1 (PD-L1)/programmed death 1(PD1) and Cytotoxic T-Lymphocyte Antigen (CTLA)\u22124 suppressors have already been utilized in some malignant cancers, but molecules that are capable of disrupting other co-suppressive signal paths are under exploration, like T cell immune globulin and T cell immunoglobulin and immune-receptor tyrosine-based inhibitory motif domain (TIGIT), lymphocyte activation gene-3 (LAG3), and T cell immunoglobulin containing the mucin domain 3 (TIM3). In the era of immune therapy, immune checkpoint inhibitors (ICIs) have been examined for HCC sufferers as well, especially, nivolumab and pembrolizumab have been accepted for second line treatment [10]. Nevertheless, resembling other gastric intestinal malignant cancers, the HCC responsive rate of ICIs as a mono therapy is low, hence new combined methods involving TACE [11,12], tyrosine kinase inhibitors (TKIs) [13], and other medicines are being investigated intensively at present. Idarubicin (IDA) is an antineoplastic drug commonly used to treat hematologic diseases. Due to their relative lipophilic properties and a longer biological half-life, this anthracycline is also used in TACE as part of HCC therapy [14]. However, conventional TACE formulations such as epirubicin-lipiodol emulsion are rapidly dissociated due to the instability of the emulsion, resulting in insufficient local drug concentrations in the target tumor. Drug eluting microbeads (DEBs) are the next generation embolic agent products of the lipiodol emulsion. They can penetrate into tumor blood vessels and release chemotherapeutic in a controlled and sustained manner [15]. Most of them are size-calibrated microspheres, typically composed of artificial polymer hydrogel, and able to block blood flow permanently. In fact, various matrix materials give microspheres different functions, such as radiopacity and absorbability. Self-visualized radiopaque microbeads would offer direct intraprocedural visual feedback regarding TACE treatment localization [16]. They could be prepared by incorporating metal elements [17] or linking iodine species to polymer chains [18,19]. To avoid long-term chronic inflammation and facilitate potential repeated treatments, biodegradable DEBs were developed [20]. For example, Okamoto et al. synthesized Lipiodol/ polycaprolactone (PCL) beads using microfluidics and air-plasma treatment, which could simultaneously release miriplatin [21]. It is worth mentioning that natural polymers are promising materials for preparing DEBs. Gelatin is a natural polymer with good biocompatibility and degradability, which has been used clinically as an embolic agent for decades [22]. Carrageenan is a polysaccharide rich in sulfate groups extracted from algae. Carrageenan has good gel ability and many biological activities, such as antibacterial, anticancer, and antiviral [23]. At present, it has been widely used in tissue engineering, regenerative medicine, and three-dimension(3D) bioprinting [24\u201326]. And the sulfated groups can rely on electrostatic adsorption to let carrageenan carry a variety of drugs, including IDA. In the present study, we used biodegradable Idarubicin loaded microspheres (BILMs), which were prepared from gelatin and carrageenan and could be loaded with IDA (IDA-MS). The morphology and the ability to load and release IDA of BILMs were characterized in vitro. In addition, we demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment. 2 Materials and methods 2.1 Preparation of BILMs Carrageenan and gelatin were brought from Aladdin Industrial Corporation. Liquid paraffin, Span 80, and isopropanol were purchased from Sinopharm Chemical Reagent Co., Ltd. Glutaraldehyde (ca. 50% in water) were purchased from TCI Shanghai and IDA(hydrochloride form) was purchased from Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. The preparation of BILMs used the emulsifying cross-linking method previously reported by Liu et al. [27]. In short, 2160 mg of carrageenan and 840 mg of gelatin were fully mixed in 50 ml of deionised water at 70 \u00b0C to form the water phase. 150 ml of liquid paraffin was mixed with 375 \u00b5l Span80 to form the oil phase. Water phase and oil phase were evenly mixed by a mechanical agitator (RW 20 digital, IKA) with 400 rpm. After maintaining 70 \u00b0C for 30 min, the whole system was immediately immersed in iced water for 30 min and cooled to about 4 \u00b0C. Subsequently, glutaraldehyde was added to the system and the dose reached 0.15% (V/V). In the whole process, the rotating speed of the mechanical mixer is maintained at 400 rpm. Finally, the solidified microspheres were recovered from the oil phase with isopropanol. The final samples were obtained after being placed in a vacuum dryer for three days. 2.2 IDA loading efficiency In this experiment, the standard curve of idarubicin concentration and optical density (OD) at 490 nm was established by using an enzyme labeling instrument (SUNRISE, TECAN) [28]. Briefly, 10 mg of idarubicin was mixed evenly with water and fixed to 5 ml to obtain a solution with a concentration of 2 mg/ml. 50 \u00b5g/ml IDA were prepared by taking 25\u00b5l of the solution and diluted to 1 ml. Then six different concentrations of IDA were obtained (50, 25, 12.5, 6.25, 3.125 and 1.5625 \u00b5g/ml). Take 200\u00b5l of each of the six samples, place them in a 96 well plate, and measure their OD at 490 nm. Subsequently, the function between OD and IDA concentration was established. 250\u00b5l idarubicin aqueous solution (2 mg/ml) was added to BILMs with a volume of 100\u00b5L after swelling [29,30]. The diameter of microspheres is 100\u2013300 \u00b5m after swelling. The BILMs and IDA were mixed evenly by shaking the container gently. Then, the microspheres and the remaining IDA solution were separated after 5 min, 10 min, 15 min, 30 min, 1 h, and 2 h. A 29 G syringe was used to separate the supernatant and microspheres. In order to collect all the IDA not carried by the microspheres, the microspheres were washed with 500\u00b5l deionised water. The supernatant and the water for washing are collected together and the volume is fixed to 2 ml. 200\u00b5l of each IDA supernatant sample was taken and measured at 490 nm and their concentration can be calculated by the function established above. Three parallel samples were set at each time point. So, the IDA loading efficiency at each time point can be obtained by the following formula: L o a d i n g e f f i c i e n c y ( % ) = i n i t i a l I D A m a s s \u2212 t h e c o n c e n t r a t i o n o f t h e r e m a i n i n g s o l u t i o n \u00d7 v o l u m e ( 2 m l ) i n i t i a l I D A m a s s \u00d7 100 % 2.3 Morphology, size, and distribution About 4 mg microspheres were soaked in water and placed on glass slides, and their appearance was observed with an optical microscope (Eclipse E200, Nikon). 200 microspheres were selected randomly and their diameters were recorded. Then a few BILMs in 2.2 mixed with IDA solution after 30 min were observed and recorded in the same way. 2.4 The release of IDA in vitro 500\u00b5l 2 mg/ml of idarubicin was added to 200\u00b5l BILMs. After loading the drug for 30 min, the microspheres were separated from the supernatant and soaked into 40 ml 0.9% NaCl saline solution [29]. The whole system is placed in a constant temperature shaker (THZ-312, Shanghai Jinghong Experimental Equipment Co., Ltd) with a temperature of 37 \u00b0C and a speed of 100 r/min. 500\u00b5l soaking solution was taken out at the time points of 15 min, 30 min, 1 h, 3 h, 6 h, 12 h, 24 h, 72 h, and 96 h, and 500\u00b5l fresh saline solution was added to maintain the total volume. The same methods were used to measure the concentration of IDA in the soaking solution. The standard curve of OD and concentration of IDA in 0.9% NaCl saline solution was established. All operations are the same as in 2.2 except for changing water into 0.9% NaCl saline solution. Thus, the cumulative drug release in the soaking solution at each time point can be calculated. There were three parallel samples. 2.5 Cell cultures The mouse HCC cell line H22 and rabbit HCC cell line VX2 were obtained from the Cell Bank of Type Culture Collection (Chinese Academy of Sciences, China). H22 and VX2 cells were cultured in RIPA 1640 medium (Gibco, USA) containing 10% FBS, 50 U. mL\u22121 penicillin (Thermo Fisher Scientific, USA), and 50 mg. mL\u22121 streptomycin (Thermo Fisher Scientific, USA). The maintenance was conducted on overall cell lines under the temperature of 37 \u00b0C within one constant\u2010temperature incubator covering 5% CO2. 2.6 Preparation of preclinical rabbit liver tumor model The animal experiment was approved by the Animal Management Committee of Nanjing Medical University, and all experimental procedures and animal care followed the institutional ethics guidelines for animal-related experiments. Male New Zealand white rabbits weighing 3.0\u20133.5 kg. The animals were housed in experimental animal-specific cages on a 12-hour light/dark cycle. Before all manipulations, animals were injected intramuscularly with 5 mg/kg body weight of thiamine-zolazepam (Zoletil 50, Virbac, Carros, France) and 2 mg/kg body weight of 2% xylazine hydrochloride (Rompun; Bayer, Seoul, South Korea). Throughout the study, the VX2 carcinoma strain was maintained in the right hindlimb of vector rabbits by deep intramuscular injection. The left lobe of the animal's liver was surgically exposed, and a small piece of fresh tumor tissue was removed from the tumor and implanted directly into the subcapsular area of the liver of each rabbit. Tumors were incubated for 17\u201318 days prior to treatment. 2.7 Rabbit liver tumor model grouping and drug delivery The animals were randomly divided into 2 groups with similar tumor volumes: animals treated with an intra-arterial (IA)infusion of IDA solution (IDA group, n = 3) and IDA-MS solution (IDA-MS group,n = 3). The dose of IDA-MS injected into liver tumor tissue was 0.5 mg. During IA delivery, a 4-French catheter (VER angiographic catheter, Cordis,USA) was inserted into the right central artery for arterial access. To access the correct hepatic artery, advance the a 2.7-Fr(French) microcatheter (Progreat Micro Catheter system, Terumo, Japan) through the catheter into the descending aorta. After hepatic arteriography was performed to confirm tumor staining and reveal the correct hepatic artery, microcatheterization was selectively performed until the catheter tip was gently placed adjacent to the proper hepatic artery. The mixture(mixtures of IDA-MS microspheres and contrast agent) prepared for each group was then gently applied under fluoroscopic guidance. After the mixture is completely injected, the microcatheter is withdrawn and the puncture site is carefully squeezed to stop the bleeding. Digital subtraction angiography (DSA) and positron emission tomography-computer tomography (PET-CT) were recorded before and after TACE treatment. 2.8 In vivo tumor mice model and treatment 20 Male C57BL/6 mice (5, 6 weeks old) were purchased from and bred under specific pathogen-free (SPF) conditions at the Nanjing Medical University Laboratory Animal Center. The mice were euthanized by cervical dislocation. To establish a subcutaneous tumor-bearing mouse model, 2 \u00d7 106 H22 cells mixed in 100\u00b5l PBS were subcutaneously inoculated into the right axillary region of C57BL/6 mice. After that, every 5 mice were randomly assigned to one group. Different groups were as follows: IDA, IDA-MS, IDA+\u03b1PD1, and IDA-MS+\u03b1PD1. When the tumors grew into 80\u2013150 mm3 in volume, IDA/IDA-MS (4 mg kg\u22121, once a week) was intratumoral injected into the mice in different groups. From the second day of injection, 200ug anti-mouse-PD1(\u03b1PD1; BE0273; Bio X Cell, USA) were injected intraperitoneally into the mice in IDA+\u03b1PD1 and IDA-MS+\u03b1PD1 groups twice a week. The tumor size was measured every 3 days and the tumor volume was calculated using the following formula: volume (mm3) = width2 \u00d7 length/2. 2.9 Hematoxylin-eosin (HE) and immunohistochemistry The HCC mouse model specimens were taken, embedded in paraffin, sectioned to 4 mm thickness, and subjected to HE stainingand immunohistochemistry according to the protocol. The dUTP -biotin nick end labeling (TUNEL) staining method in the samples used DAB (SA-HRP) TUNEL apoptosis detection kit (Servicebio, China). in 0.01 mol l-1 citrate buffer (pH 6.0; Wobixin Inc., China). Samples were blocked in PBS with 2% BSA for 1 hour at ambient temperature and were treated with monoclonal antibodies to CD3 (ab16669, 1:150 dilution; Abcam, UK), CD8 (ab217344, 1:2000 dilution; Abcam, Cambridge, UK), Ki-67 (ab16667, 1:2000 dilution; Abcam, Cambridge, UK) and PD-L1 (ab213524, 1:250 dilution; Abcam, UK), followed by enzyme-conjugated secondary antibody (ab6721, 1:1000 dilution); Abcam, UK) for 1 hour at ambient temperature. Detection was performed the next day with 3\u2032-diaminobenzidine according to the manufacturer's instructions. Images were acquired using a laser scanning confocal microscope (Zeiss, Germany). 2.10 Mass cytometry We obtained tissue samples from the IDA and IDA-MS tumor-bearing groups. We then processed mouse tumor tissue using the Miltenyi Mouse Tumor Isolation Kit (Miltenyi Biotec, Germany), in which Percoll removes debris and divides red blood cells. CyTOF staining includes the following steps: 194Pt staining\u2192Fc block staining\u2192surface antibody staining\u2192overnight DNA staining (191/193Ir)\u2192intracellular antibody staining\u2192computer acquisition of data. Data analysis steps include FlowJo preprocessing (loop and select single, live, intact CD45+ immune cells), bioinformatics analysis (X-shift algorithm performs cell subpopulation clustering, manual annotation, TSNE dimensionality reduction visual display, and statistical analysis). This experiment was carried out in PLTTECH Company (Plttech, China). 2.11 Statistical analysis Statistical analyses were carried out using the GraphPad Prism 9.0 (GraphPad software Inc., USA), and two-tailed P value < 0.05 was considered to be statistically significant. An independent t-test was used to compare the continuous variables between the two groups. 3 Results 3.1 The loading efficiency of IDA The properties of embolic microspheres play a decisive role in the therapeutic effect of TACE. BILMs prepared from carrageenan and gelatin were used. Carrageenan, the main component, could carry a variety of drugs through ion exchange mechanism. In our previous research, we have confirmed that BILMs have excellent mechanical properties, customizable size, and the ability to load and controllable release of Doxorubicin [27]. In this study, we characterized the interaction between BILMs and Idarubicin. Firstly, the standard curve between the concentration of IDA aqueous solution and the OD at 490 nm was established (Fig. 1 A). The drugs unloaded by BILMs existed in the remaining IDA solution. The concentration of the residual solution can be calculated by measuring the optical density and using the standard curve in Fig. 1A. The IDA loading efficiency was calculated as follows: L o a d i n g e f f i c i e n c y ( % ) = 500 \u03bc g \u2212 [ ( O D + 0.007095 ) \u00f7 0.009281 ] \u03bc g / m l \u00d7 2 m l 500 \u03bc g \u00d7 100 % As shown in Fig. 1B, the loading efficiency of 0.1 ml BILMs for 500 \u00b5g IDA could exceed 99% within 10 min. The effective drug loading amount of IDA was defined as 5 mg/ml microspheres. The loading efficiency reached 99.12% at 5 min, which indicated that BILMs have a good ability to carry IDA. In addition, Table 1 is listed to compare the various properties of BILMs and several commercial embolic agents [22,27\u201329,31]. Commercially available drug-eluting microspheres are usually composed of biocompatible synthetic polymers which cause permanent embolism. For example, the main components of DC Bead\u2122 and CalliSphere\u00ae are PVA. However, HCC recurs frequently and requires repeated treatment [32]. The residue of non-degradable microspheres at the lesion will lead to difficulties in subsequent embolization by occupying the route for catheterization [33]. Unlike other drug-eluting microspheres, BILMs are composed of bioabsorbable and biocompatible natural polymers. BILMs will degrade after causing intravascular embolism for a sufficient period of time, leaving space for subsequent operations. 3.2 Morphology, size, and distribution of BILMs The morphology and proper diameter distribution of microspheres is very important for catheter delivery and adequate vascular embolization. Therefore, it is necessary to study the effect of drug loading on the size and shape of BILMs [22]. An optical microscope was used to observe the morphology of BILMs before and after begin loading with IDA. It can be seen that BILMs are light yellow microspheres (Fig. 1C-a). After absorbing IDA, they turned into red-orange and maintained the same shape (Fig. 1C-b). The size and distribution of BILMs(100\u2013300 \u00b5m) in two states were also statistically analyzed. It can be seen from Fig. 1D that the size range of BILMs before and after loading IDA are basically the same. More than 99% of the microspheres are in the range of 150 \u223c 290 \u00b5m. However, the average diameter of BILMs with IDA decreased from 212.15 \u00b5m to 196.55 \u00b5m. This is due to a 17% increase in the proportion of microspheres smaller than 200 \u00b5m. 3.3 The release of IDA in vitro Similarly, the standard curve of IDA concentration in 0.9% NaCl solution and OD was established (Fig. 1E). The cumulative release of IDA in the soaking solution at each time point can be obtained by measuring the concentration of IDA in the soaking solution [34]. The cumulative release of IDA (%) was calculated as follows: C u m u l a t i v e r e l e a s e o f I D A ( % ) = t h e c u m u l a t i v e r e l e a s e o f I D A i n s o a k i n g s o l u t i o n a t e a c h t i m e p o i n t i n i t i a l I D A m a s s \u00d7 100 % = [ ( O D + 0.003104 ) \u00f7 0.008784 ] \u03bc g m l \u00d7 40 m l + x 1000 \u03bc g \u00d7 100 % x = 0.5 m l * ( I D A c o n c e n t r a t i o n a t 15 m i n + I D A c o n c e n t r a t i o n a t 30 m i n + \u2026 ) It should be noted that the drug aliquot used to analysis contains drugs, so x in the formula represents the total content of IDA in the soaking solution taken for detection before each time point. Fig. 1F showed the drug release rate of 0.2 ml BILMs loaded with about 1 mg IDA in normal saline. The bursting release of IDA was observed and the release rate reached 38.4% in 12 h. The data reached 53.43% after 24 h and the release rate exceeded 95% after 72 h. 3.4 TACE with IDA-MS significantly inhibited tumor growth in rabbit VX2 HCC model We established the rabbit VX2 HCC model using 6 rabbits, 3 for IDA-MS and 3 for IDA. As shown in Fig. 2 A, DSA results showed that TACE with IDA-MS blocked blood vessels more obviously than the IDA group. Transverse section in PET-CT images before TACE and 7 days after TACE in IDA and IDA-MS group revealed that IDA-MS group showed higher tumor reduction than the IDA group (Fig. 2B). Coronal section median sagittal section and metabolic region of rabbits\u2019 PET-CT images before TACE and 7 days after TACE in IDA and IDA-MS group also confirmed the same results (Fig. 3 A). In order to evaluate the effects of TACE with IDA-MS on tumor tissues, paracancer tissues and other important organs, we used HE staining to confirm that compared with the IDA group, TACE with IDA-MS reduced tumor infiltration, but no more severe damage to the heart, liver, spleen, lung, and kidney (Fig. 3B). 3.5 TACE with IDA-MS reduced tumor growth and increased the efficiency of anti-PD1 treatment in mice HCC model To further examine the correlation between IDA-MS and the growth of HCC in vivo, we respectively injected H22 cells with IDA, IDA-MS, IDA+\u03b1PD1, and IDA-MS+\u03b1PD1 groups into C57BL/6 mice subcutaneously, and then carried out PD1 mAb injection to assess their anti-tumor capability. More details about the experimental scheme of xenograft mice model were listed in Fig. 4 A. According to the results, compared with IDA group, the volume and weight of the tumor decreased significantly after IDA-MS injection. Compared with IDA+\u03b1PD1 group,IDA-MS+\u03b1PD1 quite decreased the tumor weight and volume (Fig. 4B-4D). PET results revealed that compared with IDA group, the concentration of the tumor decreased significantly after IDA-MS injection. Compared with IDA+\u03b1PD1 group,IDA-MS+\u03b1PD1 quite decreased the tumor concentration(Fig. 4E-4F). By HE staining, we confirmed the tumor tissue and morphologic changes in different groups. Compared with the IDA-MS group, the cells in the IDA group were more disorganized, with enlarged stained nuclei and less cytoplasmic content. In the IDA-MS+\u03b1PD1 group, tumor cells were arranged more regularly than in the previous three groups (Fig. 5 A). Given the immunohistochemical results, Ki67 expression in IDA-MS group significantly decreased compared with IDA group, and the decline was noticeably facilitated under the combination with PD1 mAb (Fig. 5A-5B). The expression of TUNEL expression was just the opposite, in line with the expected results (Fig. 5A-5B). However, the expression of CD3, CD8 and PD-L1 moderately increased after IDA-MS injection compared with IDA (Fig. 5A-5B). With the combined use of PD1 mAb in IDA+\u03b1PD1 and IDA-MS+\u03b1PD1 group, the expression of CD8 was further increased, while PD-L1 was decreased (Fig. 5A-5B). Accordingly, this study revealed injection of IDA-MS was capable of inducing apoptosis, reducing tumor growth, and enhancing the efficiency of PD1 mAb treatment in a xenograft HCC mice model in vivo. 3.6 Changes of tumor immune microenvironment after IDA-MS treatment in HCC mice model based on mass cytometry To further assess the overall immune microenvironment variations of the HCC tumors in IDA group and IDA-MS group, we used mass cytometry to measure the expression of the respective immune cell clusters. We cycled single, live, and intact CD45+ immune cells from the selected cells in the respective tissues. All samples showed clustering and subgroup annotation of CD45 + immune cells.The results showed that CD45+ immune cells was increased in IDA-MS group compared to IDA group (Fig. 6 A-6B). There were 29 cell clusters in total, and we defined the respective cell cluster based on the specific markers of the respective cell type (Figs. 6C-6D, 7 ). CD4+T cells, CD8+ T cells, natural killer (NK) cells, monocytes increased whereas macrophages decreased after IDA-MS injection compared with IDA group (Fig. 6E). Additionally, we assessed the overall expression of PD-L1(CD274), PD1(CD279), and cytokines (IFN-y, TNF-a) in the immune microenvironment. According to the results, after the injection of IDA-MS, the expression of PD-L1 and IFN-y, TNF-a increased (Fig. 8 B-8E). But PD1 showed no difference (Fig. 8A, 8E). The above results show that injection of IDA-MS could lead to the increase of PD-L1 on the surface of cancer cells, creating a tumor immune microenvironment that is conducive to the effect of PD1 mAb in HCC. 4 Discussion TACE is often the first choice for the treatment of intermediate-stage HCC and as a bridge-therapy for liver transplantation. Drug-eluting bead-TACE(DEB-TACE) is more effective and easier to tolerate than conventional TACE [35,36]. DEBs are non-absorbable embolic microspheres that can be loaded with cytotoxic agents, which were developed to achieve more sustained drug release with embolization [37,38]. The positively charged protonated amine groups present in doxorubicin and idarubicin can interact with the negatively charged sulfonates of the microspheres, which are loaded [39]. Despite no priority evidence, doxorubicin was the most commonly used drug for DEB-TACE [40]. It has been shown that the time to HCC progression was significantly better in the doxorubicin-DEB-TACE(DOX-DEB-TACE) group than in the TACE group (11.7 vs. 7.6 months) and that DEB-TACE therapy led to better treatment outcomes in intermediate stage HCC [35]. Although DOX being most commonly administered, there are no universally accepted treatment protocols in DEB-TACE, and recent studies have suggested many other drug regimens [41]. For example, DOX and radioactive species, such as iodine-131 (131I) or rhenium-188 (188Re), are attached to the microspheres matrix to achieve the combination of TACE and transarterial radioembolization (TARE) and produce a synergetic antitumor effect [42,43]. Some studies have loaded newer anti-tumor drugs into DEBs. Denys et al. studied in vivo pharmacokinetics, safety and toxicity evaluation of vandetanib eluting beads using swine liver embolization model [44]. Sakr et al. successfully loaded anti-VEGF antibodies onto the embolic microspheres and the controlled release of the drug was confirmed in vitro [45]. More and more preclinical and early clinical studies have shown that, also as an anthracycline, IDA seems to have more advantages than doxorubicin in antitumor efficacy and safety. In an in vitro study of the cytotoxicity of anticancer drugs on three human hepatoma cells, idarubicin showed the most active anticancer effect compared with doxorubicin and 9 other common chemotherapeutic drugs [39]. Furthermore, with reference to doxorubicin in rapid infusion, the relative cardiotoxicity of idarubicin was 0.53, and idarubicin required less therapeutic dose [46]. A multicenter, prospective, single-arm, phase II clinical trial reported a 6-month objective response rate of 52% in patients with advanced HCC in the study using idarubicin-DEBs (IDA-DEBs) for TACE, and median overall survival was 18.6 months [30]. In addition, this study had a lower incidence of treatment discontinuation (9% vs 29%) compared to doxorubicin-eluting beads plus placebo arm of the sorafenib or placebo plus TACE trial [47]. Also, the majority of grade 3\u20134 TACE-related adverse events in subjects with IDA-DEB-TACE were biological/transient without any sequelae [30]. Small diameter beads have been shown to cause total necrosis of the target lesion because smaller diameter beads can be embolized more distally and thus block collateral channels [35], but 40 \u00b5m microspheres may be more toxic due to the dependent of size compared to 100 \u00b5m microspheres [48]. In this study, diameter of the 99% microspheres used in loading IDA is 150 \u223c 290 \u00b5m, and the IDA-MS was promising to be developed as a new TACE formulation to overcome the poor delivery of drugs due to rapid elimination of the anticancer drug into the systemic circulation. In addition, we demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in tumor shrinkage and no more severe adverse events than those observed in the IDA group. In the rabbit experiment, IDA also showed noteworthy anti-tumor effect even without loaded microspheres, which may be due to the high lipophilicity of IDA, resulting in higher cell penetration of lipid membrane and more drug accumulation in lipiodol, which eventually exerted anti-tumor effects [49,50]. In the murine model, we validated the anti-tumor efficacy by subcutaneous intratumoral injection. However, in experiments with mice, we found that IDA alone did not seem to demonstrate such a powerful cancer-inhibiting effect after intratumoral injection into rat subcutaneous tumors. This may be due to that the intratumorally injected IDA was metabolized too quickly and failed to exert cytotoxicity in a sustained manner. Furthermore, we found that the anti-cancer efficacy in the IDA-MS group was increased compared with the IDA group, which may have confirmed this view from another aspect. In this study, we firstly demonstrated that intratumoral injection of IDA-MS would contribute to enhancing the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. It has been reported blocking PD1/PD-L1, nivolumab [51] and camrelizumab [52], indicated the substantial anti-tumor effect on patients with advanced HCC [51\u201353], which brought new solutions to HCC treatment. However, in clinical practice, a considerable number of patients had no response to anti-PD1 immunotherapy and develop drug resistance. The expression of PD-L1 could be used as a predictor of anti-PD1 immunotherapy, and lack of PD-L1 expression was an important mechanism of resistance to anti-PD1/PD-L1 therapies [54]. In this study, in contrast to the depletion of PD-L1 expression in the IDA group, the expression of PD-L1 was significantly increased after the intratumoral injection of IDA-loaded microspheres, which led to immune activation. Moreover, in this study, mass cytometry was used to more comprehensively analyze changes in the tumor microenvironment. The newly synthesized IDA-MS in our study not only increased the expression of PD-L1 in the tumor, but also increased the expression of CD8+ T cells, NK cells and IFN-g, and these interventions jointly promoted the activation of immune function. It opened up a new regimen for anti-PD1 immunotherapy in cancer. Our experiments also have some limitations. Firstly, we failed to simulate IDA-MS enhancing PD1/PD-L1 blockade therapy in the rabbit liver cancer model due to the failure to find the PD1 mAb against rabbits. Secondly, mass cytometry cannot eliminate the heterogeneous information of tumor cells, and more accurate sequencing techniques such as single-cell sequencing should be used for specific cell population sequencing analyses. Thirdly, we still need to further explore the mechanism by which intratumoral injection of IDA-MS led to the marked elevation of PD-L1. At last, our study is mainly limited to animal experiments, and further clinical trials are needed to verify the reliability of the conclusions of this study. 5 Conclusion In summary, the present study reveals that the IDA-MS is developed as a new TACE formulation to overcome the poor delivery of drugs due to rapid elimination of the anticancer drug into the systemic circulation. TACE with IDA-MS resulted in tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment. Funding This work was supported by the grants from National Key Research and Development Program of China (Grant No.2017YFA0205501), the National Natural Science Foundation of China (Grant No.82073804). Details of authors' contributions 4 first authors were listed in this manuscript. Dr. ZYZ, MXM, XPH and XL were responsible for designing the study, performing part of the experiments, as well as drafting the manuscript. Furthermore, we have 5 corresponding authors in this manuscript. Dr. JHS, FX, GGS, WWT and JK have contributed to the study design, data interpretation, editing, and critical revision of the manuscript. Other authors also contributed to performing part of the experiments, and data interpretation. All authors read and approved the final manuscript. Declaration of Competing Interest The authors declare that they have no competing interests. Acknowledgments None. References [1] V. Treska J. Bruha V. Liska J. Fichtl K. Prochazkova T. Petrakova P. Hosek Pros and cons of portal vein embolization with hematopoietic stem cells application in colorectal liver metastases surgery In Vivo 34 5 2020 2919 2925 (Brooklyn)Sep-Oct Treska V., Bruha J., Liska V., Fichtl J., Prochazkova K., Petrakova T., Hosek P. Pros and cons of portal vein embolization with hematopoietic stem cells application in colorectal liver metastases surgery. In Vivo (Brooklyn). 2020 Sep-Oct;34(5):2919\u20132925. [2] Y. Collin A. Par\u00e9 A. Belblidia R. L\u00e9tourneau M. Plasse M. Dagenais S. Turcotte G. Martel A. Roy R. Lapointe F. Vandenbroucke-Menu Portal vein embolization does not affect the long-term survival and risk of cancer recurrence among colorectal liver metastases patients: a prospective cohort study Int. J. Surg. 61 2019 42 47 Jan Collin Y., Par\u00e9 A., Belblidia A., L\u00e9tourneau R., Plasse M., Dagenais M., Turcotte S., Martel G., Roy A., Lapointe R., Vandenbroucke-Menu F. Portal vein embolization does not affect the long-term survival and risk of cancer recurrence among colorectal liver metastases patients: a prospective cohort study. Int. J. Surg.. 2019 Jan;61:42\u201347. [3] D.C. Madoff B.C. Odisio E. Schadde R.C. Gaba R.J. Bennink T.M. van Gulik B. Guiu Improving the safety of major resection for hepatobiliary malignancy: portal vein embolization and recent innovations in liver regeneration strategies Curr. Oncol. Rep. 22 6 2020 59 May 16 Madoff D.C., Odisio B.C., Schadde E., Gaba R.C., Bennink R.J., van Gulik T.M., Guiu B. Improving the safety of major resection for hepatobiliary malignancy: portal vein embolization and recent innovations in liver regeneration strategies. Curr. Oncol. Rep.. 2020 May 16;22(6):59. [4] E. Chakraborty D. Sarkar Emerging therapies for hepatocellular carcinoma (HCC) Cancers 14 11 2022 2798 (Basel)Jun 4 Chakraborty E., Sarkar D. Emerging therapies for hepatocellular carcinoma (HCC). Cancers (Basel). 2022 Jun 4;14(11):2798. [5] J. Willatt K.K. Hannawa J.A. Ruma T.L. Frankel D. Owen P.M. Barman Image-guided therapies in the treatment of hepatocellular carcinoma: a multidisciplinary perspective World J. Hepatol. 7 2 2015 235 244 Feb 27 Willatt J., Hannawa K.K., Ruma J.A., Frankel T.L., Owen D., Barman P.M. Image-guided therapies in the treatment of hepatocellular carcinoma: a multidisciplinary perspective. World J. Hepatol.. 2015 Feb 27;7(2):235\u201344. [6] R.C. Gaba R. Emmadi A. Parvinian L.C. Casadaban Correlation of doxorubicin delivery and tumor necrosis after drug-eluting bead transarterial chemoembolization of rabbit VX2 liver tumors Radiology 280 3 2016 752 761 Sep Gaba R.C., Emmadi R., Parvinian A., Casadaban L.C. Correlation of doxorubicin delivery and tumor necrosis after drug-eluting bead transarterial chemoembolization of rabbit VX2 liver tumors. Radiology. 2016 Sep;280(3):752\u201361. [7] J.M.M. van Breugel J.F. Geschwind S. Mirpour L.J. Savic X. Zhang R. Duran M. Lin M. Miszczuk E. Liapi J. Chapiro Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model Theranostics 9 13 2019 3674 3686 May 27 van Breugel J.M.M., Geschwind J.F., Mirpour S., Savic L.J., Zhang X., Duran R., Lin M., Miszczuk M., Liapi E., Chapiro J. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics. 2019 May 27;9(13):3674\u20133686. [8] J.M. Llovet J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2 2003 429 442 Feb Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003 Feb;37(2):429\u201342. [9] W. Ma J. Jia S. Wang W. Bai J. Yi M. Bai Z. Quan Z. Yin D. Fan J. Wang G. Han The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE) Theranostics 4 7 2014 736 744 May 1 Ma W., Jia J., Wang S., Bai W., Yi J., Bai M., Quan Z., Yin Z., Fan D., Wang J., Han G. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics. 2014 May 1;4(7):736\u201344. [10] V. Longo A. Gnoni A. Casadei Gardini S. Pisconti A. Licchetta M. Scartozzi R. Memeo V.O. Palmieri G. Aprile D. Santini P. Nardulli N. Silvestris O. Brunetti Immunotherapeutic approaches for hepatocellular carcinoma Oncotarget 8 20 2017 33897 33910 May 16 Longo V., Gnoni A., Casadei Gardini A., Pisconti S., Licchetta A., Scartozzi M., Memeo R., Palmieri V.O., Aprile G., Santini D., Nardulli P., Silvestris N., Brunetti O.. Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget. 2017 May 16;8(20):33897\u201333910. [11] O.B. Gbolahan M.A. Schacht E.W. Beckley T.P. LaRoche B.H. O'Neil M. Pyko Locoregional and systemic therapy for hepatocellular carcinoma J. Gastrointest Oncol. 8 2 2017 215 228 Apr Gbolahan O.B., Schacht M.A., Beckley E.W., LaRoche T.P., O'Neil B.H., Pyko M.. Locoregional and systemic therapy for hepatocellular carcinoma. J. Gastrointest Oncol.. 2017 Apr;8(2):215\u2013228. [12] A.S. Mikhail M. Mauda-Havakuk A.H. Negussie N. Hong N.M. Hawken C.J. Carlson J.W. Owen O. Franco-Mahecha P.G. Wakim A.L. Lewis W.F. Pritchard J.W. Karanian B.J. Wood Evaluation of immune-modulating drugs for use in drug-eluting microsphere transarterial embolization Int. J. Pharm. 616 2022 121466 Mar 25 Mikhail A.S., Mauda-Havakuk M., Negussie A.H., Hong N., Hawken N.M., Carlson C.J., Owen J.W., Franco-Mahecha O., Wakim P.G., Lewis A.L., Pritchard W.F., Karanian J.W., Wood B.J. Evaluation of immune-modulating drugs for use in drug-eluting microsphere transarterial embolization. Int. J. Pharm.. 2022 Mar 25;616:121466. [13] H. Li C.W. Li X. Li Q. Ding L. Guo S. Liu C. Liu C.C. Lai J.M. Hsu Q. Dong W. Xia J.L. Hsu H. Yamaguchi Y. Du Y.J. Lai X. Sun P.B. Koller Q. Ye M.C. Hung MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1 Gastroenterology 156 6 2019 1849 1861 Maye13 Li H., Li C.W., Li X., Ding Q., Guo L., Liu S., Liu C., Lai C.C., Hsu J.M., Dong Q., Xia W., Hsu J.L., Yamaguchi H., Du Y., Lai Y.J., Sun X., Koller P.B., Ye Q., Hung M.C. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology. 2019 May;156(6):1849\u20131861.e13. [14] B. Bourcier F. Lagarce V. Lebreton Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization J. Pharm. Biomed. Anal. 210 2022 114543 Feb 20 Bourcier B., Lagarce F., Lebreton V. Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization. J. Pharm. Biomed. Anal.. 2022 Feb 20;210:114543. [15] A.L. Lewis S.L. Willis M.R. Dreher Y. Tang K. Ashrafi B.J. Wood E.B. Levy K.V. Sharma A.H. Negussie A.S. Mikhail Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance Future Oncol. 14 26 2018 2741 2760 Nov Lewis A.L., Willis S.L., Dreher M.R., Tang Y., Ashrafi K., Wood B.J., Levy E.B., Sharma K.V., Negussie A.H., Mikhail A.S. Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance. Future Oncol.. 2018 Nov;14(26):2741\u20132760. [16] A.S. Mikhail W.F. Pritchard A.H. Negussie G. Inkiyad D.J. Long M. Mauda-Havakuk P.G. Wakim W. van der Sterren E.B. Levy A.L. Lewis J.W. Karanian B.J. Wood Cone-beam computed tomography-based spatial prediction of drug dose after transarterial chemoembolization using radiopaque drug-eluting beads in woodchuck hepatocellular carcinoma Invest Radiol. 57 8 2022 495 501 Aug 1 Mikhail A.S., Pritchard W.F., Negussie A.H., Inkiyad G., Long D.J., Mauda-Havakuk M., Wakim P.G., van der Sterren W., Levy E.B., Lewis A.L., Karanian J.W., Wood B.J. Cone-beam computed tomography-based spatial prediction of drug dose after transarterial chemoembolization using radiopaque drug-eluting beads in woodchuck hepatocellular carcinoma. Invest Radiol.. 2022 Aug 1;57(8):495\u2013501. [17] A.H. Negussie Q.M.B. de Ruiter H. Britton D.R. Donahue Q. Boffi Y.S. Kim W.F. Pritchard C. Moonen G. Storm A.L. Lewis B.J. Wood Synthesis, characterization, and imaging of radiopaque bismuth beads for image-guided transarterial embolization Sci. Rep. 11 1 2021 533 Jan 12 Negussie A.H., de Ruiter Q.M.B., Britton H., Donahue D.R., Boffi Q., Kim Y.S., Pritchard W.F., Moonen C., Storm G., Lewis A.L., Wood B.J. Synthesis, characterization, and imaging of radiopaque bismuth beads for image-guided transarterial embolization. Sci. Rep.. 2021 Jan 12;11(1):533. [18] R. Duran K. Sharma M.R. Dreher K. Ashrafi S. Mirpour M. Lin R.E. Schernthaner T.R. Schlachter V. Tacher A.L. Lewis S. Willis M. den Hartog A. Radaelli A.H. Negussie B.J. Wood J.F. Geschwind A novel inherently radiopaque bead for transarterial embolization to treat liver cancer - a pre-clinical study Theranostics 6 1 2016 28 39 Jan 1 Duran R., Sharma K., Dreher M.R., Ashrafi K., Mirpour S., Lin M., Schernthaner R.E., Schlachter T.R., Tacher V., Lewis A.L., Willis S., den Hartog M., Radaelli A., Negussie A.H., Wood B.J., Geschwind J.F. A novel inherently radiopaque bead for transarterial embolization to treat liver cancer - a pre-clinical study. Theranostics. 2016 Jan 1;6(1):28\u201339. [19] K. Ashrafi Y. Tang H. Britton O. Domenge D. Blino A.J. Bushby K. Shuturminska M. den Hartog A. Radaelli A.H. Negussie A.S. Mikhail D.L. Woods V. Krishnasamy E.B. Levy B.J. Wood S.L. Willis M.R. Dreher A.L. Lewis Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI\u2122 J. Control Release 250 2017 36 47 Mar 28 Ashrafi K., Tang Y., Britton H., Domenge O., Blino D., Bushby A.J., Shuturminska K., den Hartog M., Radaelli A., Negussie A.H., Mikhail A.S., Woods D.L., Krishnasamy V., Levy E.B., Wood B.J., Willis S.L., Dreher M.R., Lewis A.L. Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI\u2122. J. Control Release. 2017 Mar 28;250:36\u201347. [20] Y.S. Liu X.Z. Lin H.M. Tsai H.W. Tsai G.C. Chen S.F. Chen J.W. Kang C.M. Chou C.Y. Chen Development of biodegradable radiopaque microsphere for arterial embolization-a pig study World J. Radiol. 7 8 2015 212 219 Aug 28 Liu Y.S., Lin X.Z., Tsai H.M., Tsai H.W., Chen G.C., Chen S.F., Kang J.W., Chou C.M., Chen C.Y. Development of biodegradable radiopaque microsphere for arterial embolization-a pig study. World J. Radiol. 2015 Aug 28;7(8):212\u20139. [21] Y. Okamoto T. Hasebe K. Bito K. Yano T. Matsumoto K. Tomita A. Hotta Fabrication of radiopaque drug-eluting beads based on lipiodol/biodegradable-polymer for image-guided transarterial chemoembolization of unresectable hepatocellular carcinoma Polym. Degrad. Stab. 175 2020 109106 May Okamoto Y., Hasebe T., Bito K., Yano K., Matsumoto T., Tomita K., Hotta A. Fabrication of radiopaque drug-eluting beads based on lipiodol/biodegradable-polymer for image-guided transarterial chemoembolization of unresectable hepatocellular carcinoma. Polym. Degrad. Stab.. 2020 May;175:109106. [22] A. Poursaid M.M. Jensen E. Huo H. Ghandehari Polymeric materials for embolic and chemoembolic applications J. Control Release 240 2016 414 433 Oct 28 Poursaid A., Jensen M.M., Huo E., Ghandehari H. Polymeric materials for embolic and chemoembolic applications. J. Control Release. 2016 Oct 28;240:414\u2013433. [23] A. Jafari M. Farahani M. Sedighi N. Rabiee H. Savoji Carrageenans for tissue engineering and regenerative medicine applications: a review Carbohydr. Polym. 281 2022 119045 Apr 1 Jafari A., Farahani M., Sedighi M., Rabiee N., Savoji H. Carrageenans for tissue engineering and regenerative medicine applications: a review. Carbohydr. Polym.. 2022 Apr 1;281:119045. [24] S.M. Mihaila A.K. Gaharwar R.L. Reis A.P. Marques M.E. Gomes A. Khademhosseini Photocrosslinkable kappa-carrageenan hydrogels for tissue engineering applications Adv. Healthc. Mater. 2 6 2013 895 907 Jun Mihaila S.M., Gaharwar A.K., Reis R.L., Marques A.P., Gomes M.E., Khademhosseini A. Photocrosslinkable kappa-carrageenan hydrogels for tissue engineering applications. Adv. Healthc. Mater.. 2013 Jun;2(6):895\u2013907. [25] M.P. Rode A.B. Batti Angulski F.A. Gomes M.M. da Silva T.D.S. Jeremias R.G. de Carvalho D.G. Iucif Vieira L.F.C. Oliveira L. Fernandes Maia A.G. Trentin L. Hayashi K.R. de Miranda A.K. de Aguiar R.D. Rosa G.W Calloni Carrageenan hydrogel as a scaffold for skin-derived multipotent stromal cells delivery J. Biomater. Appl. 33 3 2018 422 434 Sep Rode M.P., Batti Angulski A.B., Gomes F.A., da Silva M.M., Jeremias T.D.S., de Carvalho R.G., Iucif Vieira D.G., Oliveira L.F.C., Fernandes Maia L., Trentin A.G., Hayashi L., de Miranda K.R., de Aguiar A.K., Rosa R.D., Calloni G.W. Carrageenan hydrogel as a scaffold for skin-derived multipotent stromal cells delivery. J. Biomater. Appl.. 2018 Sep;33(3):422\u2013434. [26] S.E. Bakarich P. Balding I.II.R. Gorkin G.M. Spinks M.I.H. Panhuis Printed ionic-covalent entanglement hydrogels from carrageenan and an epoxy amine RSC Adv. 4 72 2014 38088 38092 Aug Bakarich S.E., Balding P., Gorkin I.II.R., Spinks G.M., Panhuis M.I.H. Printed ionic-covalent entanglement hydrogels from carrageenan and an epoxy amine. RSC Adv.. 2014 Aug;4(72):38088\u201338092. [27] L. Kunliang J. Zhicheng H. Xiaolong Y. Dan Z. Yu Z. Haidong T. Gaojun X. Fei A biodegradable multifunctional porous microsphere composed of carrageenan for promoting imageable trans-arterial chemoembolization Int. J. Biol. Macromol. 142 2020 866 878 Jan 1 Kunliang L., Zhicheng J., Xiaolong H., Dan Y., Yu Z., Haidong Z., Gaojun T., Fei X. A biodegradable multifunctional porous microsphere composed of carrageenan for promoting imageable trans-arterial chemoembolization. Int. J. Biol. Macromol.. 2020 Jan 1;142:866\u2013878. [28] G. Go\u0142u\u0144ski A. Borowik A. Lipi\u0144ska M. Romanik N. Derewo\u0144ko A. Woziwodzka J. Piosik Pentoxifylline affects idarubicin binding to DNA Bioorg Chem. 65 2016 118 125 Apr Go\u0142u\u0144ski G., Borowik A., Lipi\u0144ska A., Romanik M., Derewo\u0144ko N., Woziwodzka A., Piosik J. Pentoxifylline affects idarubicin binding to DNA. Bioorg Chem.. 2016 Apr;65:118\u201325. [29] B. Guiu G. Hincapie L. Thompson Y. Wu M. Boulin C. Cassinotto G.M. Cruise An in vitro evaluation of four types of drug-eluting embolics loaded with idarubicin J. Vasc. Interv. Radiol. 30 8 2019 1303 1309 Aug Guiu B., Hincapie G., Thompson L., Wu Y., Boulin M., Cassinotto C., Cruise G.M. An in vitro evaluation of four types of drug-eluting embolics loaded with idarubicin. J. Vasc. Interv. Radiol.. 2019 Aug;30(8):1303\u20131309. [30] B. Guiu P. Chevallier E. Assenat E. Barbier P. Merle A. Bouvier J. Dumortier E. Nguyen-Khac J. Gugenheim A. Rode F. Oberti P.J. Valette T. Yzet O. Chevallier J.C. Barbare M. Latournerie M. Boulin Idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma: the IDASPHERE II single-arm phase II trial Radiology 291 3 2019 801 808 Jun Guiu B., Chevallier P., Assenat E., Barbier E., Merle P., Bouvier A., Dumortier J., Nguyen-Khac E., Gugenheim J., Rode A., Oberti F., Valette P.J., Yzet T., Chevallier O., Barbare J.C., Latournerie M., Boulin M. Idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma: the IDASPHERE II single-arm phase II trial. Radiology. 2019 Jun;291(3):801\u2013808. [31] J. Delicque B. Guiu M. Boulin H. Schwanz L. Piron C. Cassinotto Liver chemoembolization of hepatocellular carcinoma using TANDEM\u00ae microspheres Future Oncol. 14 26 2018 2761 2772 Nov Delicque J., Guiu B., Boulin M., Schwanz H., Piron L., Cassinotto C. Liver chemoembolization of hepatocellular carcinoma using TANDEM\u00ae microspheres. Future Oncol.. 2018 Nov;14(26):2761\u20132772. [32] V. Verret J.P. Pelage M. Wassef S. Louguet E. Servais L. B\u00e9douet T. Beaulieu L. Moine A. Laurent A novel resorbable embolization microsphere for transient uterine artery occlusion: a comparative study with trisacryl-gelatin microspheres in the sheep model J. Vasc. Interv. Radiol. 25 11 2014 1759 1766 Nov Verret V., Pelage J.P., Wassef M., Louguet S., Servais E., B\u00e9douet L., Beaulieu T., Moine L., Laurent A. A novel resorbable embolization microsphere for transient uterine artery occlusion: a comparative study with trisacryl-gelatin microspheres in the sheep model. J. Vasc. Interv. Radiol.. 2014 Nov;25(11):1759\u201366. [33] S.I. Jeon M.S. Kim H.J. Kim Y.I. Kim H.J. Jae C.H. Ahn Biodegradable poly(lactide-co-glycolide) microspheres encapsulating hydrophobic contrast agents for transarterial chemoembolization J. Biomater. Sci. Polym. Ed. 33 4 2022 409 425 Mar Jeon S.I., Kim M.S., Kim H.J., Kim Y.I., Jae H.J., Ahn C.H. Biodegradable poly(lactide-co-glycolide) microspheres encapsulating hydrophobic contrast agents for transarterial chemoembolization. J. Biomater. Sci. Polym. Ed.. 2022 Mar;33(4):409\u2013425. [34] M.V. Gonzalez Y. Tang G.J. Phillips A.W. Lloyd B. Hall P.W. Stratford A.L. Lewis Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation J. Mater. Sci. Mater. Med. 19 2 2008 767 775 Feb Gonzalez M.V., Tang Y., Phillips G.J., Lloyd A.W., Hall B., Stratford P.W., Lewis A.L. Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation. J. Mater. Sci. Mater. Med.. 2008 Feb;19(2):767\u201375. [35] M.J. Song H.J. Chun D.S. Song H.Y. Kim S.H. Yoo C.H. Park S.H. Bae J.Y. Choi U.I. Chang J.M. Yang H.G. Lee S.K. Yoon Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma J. Hepatol. 57 6 2012 1244 1250 Dec Song M.J., Chun H.J., Song D.S., Kim H.Y., Yoo S.H., Park C.H., Bae S.H., Choi J.Y., Chang U.I., Yang J.M., Lee H.G., Yoon S.K. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J. Hepatol.. 2012 Dec;57(6):1244\u201350. [36] M. Boulin P. Hillon J.P. Cercueil F. Bonnetain S. Dabakuyo A. Minello J.L. Jouve C. Lepage M. Bardou M. Wendremaire P. Guerard A. Denys A. Grandvuillemin B. Chauffert L. Bedenne B. Guiu Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial Aliment Pharmacol. Ther. 39 11 2014 1301 1313 Jun Boulin M., Hillon P., Cercueil J.P., Bonnetain F., Dabakuyo S., Minello A., Jouve J.L., Lepage C., Bardou M., Wendremaire M., Guerard P., Denys A., Grandvuillemin A., Chauffert B., Bedenne L., Guiu B. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol. Ther.. 2014 Jun;39(11):1301\u201313. [37] G.H. Zhou J. Han J.H. Sun Y.L. Zhang T.Y. Zhou C.H. Nie T.Y. Zhu S.Q. Chen B.Q. Wang Z.N. Yu H.L. Wang L.M. Chen W.L. Wang S.S. Zheng Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres\u00ae beads in Chinese hepatocellular carcinoma patients BMC Cancer 18 1 2018 644 Jun 8 Zhou G.H., Han J., Sun J.H., Zhang Y.L., Zhou T.Y., Nie C.H., Zhu T.Y., Chen S.Q., Wang B.Q., Yu Z.N., Wang H.L., Chen L.M., Wang W.L., Zheng S.S. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres\u00ae beads in Chinese hepatocellular carcinoma patients. BMC Cancer. 2018 Jun 8;18(1):644. [38] M. Boulin A. Schmitt E. Delhom J.P. Cercueil M. Wendremaire D.C. Imbs A. Fohlen F. Panaro A. Herrero A. Denys B. Guiu Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: proof of concept using idarubicin Eur. Radiol. 26 2 2016 601 609 Boulin M., Schmitt A., Delhom E., Cercueil J.P., Wendremaire M., Imbs D.C., Fohlen A., Panaro F., Herrero A., Denys A., Guiu B., Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: proof of concept using idarubicin, Eur. Radiol. 26(2) (2016) 601\u20139. [39] M. Boulin S. Guiu B. Chauffert S. Aho J.P. Cercueil F. Ghiringhelli D. Krause P. Fagnoni P. Hillon L. Bedenne B. Guiu Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma Anticancer Drugs 22 8 2011 741 748 Sep Boulin M., Guiu S., Chauffert B., Aho S., Cercueil J.P., Ghiringhelli F., Krause D., Fagnoni P., Hillon P., Bedenne L., Guiu B. Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs. 2011 Sep;22(8):741\u20138. [40] G.S. Roth Y. Teyssier M. Abousalihac A. Seigneurin J. Ghelfi C. Sengel T. Decaens Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma World J. Gastroenterol. 26 3 2020 324 334 Jan 21 Roth G.S., Teyssier Y., Abousalihac M., Seigneurin A., Ghelfi J., Sengel C., Decaens T. Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. World J. Gastroenterol.. 2020 Jan 21;26(3):324\u2013334. [41] R. Duran J. Namur F. Pascale P. Czuczman Z. Bascal H. Kilpatrick R. Whomsley S. Ryan A.L. Lewis A. Denys Vandetanib-eluting radiopaque beads: pharmacokinetics, safety, and efficacy in a rabbit model of liver cancer Radiology 293 3 2019 695 703 Dec Duran R., Namur J., Pascale F., Czuczman P., Bascal Z., Kilpatrick H., Whomsley R., Ryan S., Lewis A.L., Denys A.. Vandetanib-eluting radiopaque beads: pharmacokinetics, safety, and efficacy in a rabbit model of liver cancer. Radiology. 2019 Dec;293(3):695\u2013703. [42] Y. Qian Q. Liu P. Li Y. Han J. Zhang J. Xu J. Sun A. Wu S. Song W. Lu Highly tumor-specific and long-acting iodine-131 microbeads for enhanced treatment of hepatocellular carcinoma with low-dose radio-chemoembolization ACS Nano 15 2 2021 2933 2946 Feb 23 Qian Y., Liu Q., Li P., Han Y., Zhang J., Xu J., Sun J., Wu A., Song S., Lu W. Highly tumor-specific and long-acting iodine-131 microbeads for enhanced treatment of hepatocellular carcinoma with low-dose radio-chemoembolization. ACS Nano. 2021 Feb 23;15(2):2933\u20132946. [43] P.F. Chiang C.L. Peng Y.H. Shih Y.H. Cho C.S. Yu Y.M. Kuo M.J. Shieh T.Y. Luo Biodegradable and multifunctional microspheres for treatment of hepatoma through transarterial embolization ACS Biomater. Sci. Eng. 4 9 2018 3425 3433 Sep 10 Chiang P.F., Peng C.L., Shih Y.H., Cho Y.H., Yu C.S., Kuo Y.M., Shieh M.J., Luo T.Y. Biodegradable and multifunctional microspheres for treatment of hepatoma through transarterial embolization. ACS Biomater. Sci. Eng.. 2018 Sep 10;4(9):3425\u20133433. [44] A. Denys P. Czuczman D. Grey Z. Bascal R. Whomsley H. Kilpatrick A.L. Lewis Vandetanib-eluting radiopaque beads: in vivo pharmacokinetics, safety and toxicity evaluation following swine liver embolization Theranostics. 7 8 2017 2164 2176 Jun 1 Denys A., Czuczman P., Grey D., Bascal Z., Whomsley R., Kilpatrick H., Lewis A.L. Vandetanib-eluting radiopaque beads: in vivo pharmacokinetics, safety and toxicity evaluation following swine liver embolization. Theranostics. 2017 Jun 1;7(8):2164\u20132176. [45] O.S. Sakr S. Berndt G. Carpentier M. Cuendet O. Jordan G. Borchard Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology J. Control Release 224 2016 199 207 Feb 28 Sakr O.S., Berndt S., Carpentier G., Cuendet M., Jordan O., Borchard G. Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology. J. Control Release. 2016 Feb 28;224:199\u2013207. [46] J.L. Zamorano P. Lancellotti D. Rodriguez Mu\u00f1oz V. Aboyans R. Asteggiano M. Galderisi G. Habib D.J. Lenihan G.Y.H. Lip A.R. Lyon T. Lopez Fernandez D. Mohty M.F. Piepoli J. Tamargo A. Torbicki T.M. Suter ESC Scientific Document Group 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC) Eur. Heart J. 37 36 2016 2768 2801 Sep 21 Zamorano J.L., Lancellotti P., Rodriguez Mu\u00f1oz D., Aboyans V., Asteggiano R., Galderisi M., Habib G., Lenihan D.J., Lip G.Y.H., Lyon A.R., Lopez Fernandez T., Mohty D., Piepoli M.F., Tamargo J., Torbicki A., Suter T.M.; ESC Scientific Document Group. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur. Heart J.. 2016 Sep 21;37(36):2768\u20132801. [47] R. Lencioni J.M. Llovet G. Han W.Y. Tak J. Yang A. Guglielmi S.W. Paik M. Reig D.Y. Kim G.Y. Chau A. Luca L.R. Del Arbol M.A. Leberre W. Niu K. Nicholson G. Meinhardt J. Bruix Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial J. Hepatol. 64 5 2016 1090 1098 May Lencioni R., Llovet J.M., Han G., Tak W.Y., Yang J., Guglielmi A., Paik S.W., Reig M., Kim D.Y., Chau G.Y., Luca A., Del Arbol L.R., Leberre M.A., Niu W., Nicholson K., Meinhardt G., Bruix J. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J. Hepatol.. 2016 May;64(5):1090\u20131098. [48] T. Borde F. Laage Gaupp J.F. Geschwind L.J. Savic M. Miszczuk I. Rexha L. Adam J.J. Walsh S. Huber J.S. Duncan D.C. Peters A. Sinusas T. Schlachter B. Gebauer F. Hyder D. Coman J.M.M. van Breugel J. Chapiro Idarubicin-loaded ONCOZENE drug-eluting bead chemoembolization in a rabbit liver tumor model: investigating safety, therapeutic efficacy, and effects on tumor microenvironment J. Vasc. Interv. Radiol. 31 10 2020 1706 1716 Octe1 Borde T., Laage Gaupp F., Geschwind J.F., Savic L.J., Miszczuk M., Rexha I., Adam L., Walsh J.J., Huber S., Duncan J.S., Peters D.C., Sinusas A., Schlachter T., Gebauer B., Hyder F., Coman D., van Breugel J.M.M., Chapiro J.. Idarubicin-loaded ONCOZENE drug-eluting bead chemoembolization in a rabbit liver tumor model: investigating safety, therapeutic efficacy, and effects on tumor microenvironment. J. Vasc. Interv. Radiol.. 2020 Oct;31(10):1706\u20131716.e1. [49] S. Favelier M. Boulin S. Hamza J.P. Cercueil V. Cherblanc C. Lepage P. Hillon B. Chauffert D. Kraus\u00e9 B. Guiu Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience Cardiovasc Intervent Radiol 36 4 2013 1039 1046 Aug Favelier S., Boulin M., Hamza S., Cercueil J.P., Cherblanc V., Lepage C., Hillon P., Chauffert B., Kraus\u00e9 D., Guiu B. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience. Cardiovasc Intervent Radiol. 2013 Aug;36(4):1039\u201346. [50] B. Guiu J.L. Jouve A. Schmitt A. Minello F. Bonnetain C. Cassinotto L. Piron J.P. Cercueil R. Loffroy M. Latournerie M. Wendremaire C. Lepage M. Boulin Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: the LIDA-B phase I trial J. Hepatol. 68 6 2018 1163 1171 Jun Guiu B., Jouve J.L., Schmitt A., Minello A., Bonnetain F., Cassinotto C., Piron L., Cercueil J.P., Loffroy R., Latournerie M., Wendremaire M., Lepage C., Boulin M. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: the LIDA-B phase I trial. J. Hepatol.. 2018 Jun;68(6):1163\u20131171. [51] A.B. El-Khoueiry B. Sangro T. Yau T.S. Crocenzi M. Kudo C. Hsu T.Y. Kim S.P. Choo J. Trojan W.T.H. Rd T. Meyer Y.K. Kang W. Yeo A. Chopra J. Anderson C. Dela Cruz L. Lang J. Neely H. Tang H.B. Dastani I. Melero Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet 389 10088 2017 2492 2502 Jun 24 El-Khoueiry A.B., Sangro B., Yau T., Crocenzi T.S., Kudo M., Hsu C., Kim T.Y., Choo S.P., Trojan J., Rd W.T.H., Meyer T., Kang Y.K., Yeo W., Chopra A., Anderson J., Dela Cruz C., Lang L., Neely J., Tang H., Dastani H.B., Melero I.. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492\u20132502. [52] S. Qin Z. Ren Z. Meng Z. Chen X. Chai J. Xiong Y. Bai L. Yang H. Zhu W. Fang X. Lin X. Chen E. Li L. Wang C. Chen J. Zou Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial Lancet Oncol. 21 4 2020 571 580 Apr Qin S., Ren Z., Meng Z., Chen Z., Chai X., Xiong J., Bai Y., Yang L., Zhu H., Fang W., Lin X., Chen X., Li E., Wang L., Chen C., Zou J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol.. 2020 Apr;21(4):571\u2013580. [53] R.S. Finn S. Qin M. Ikeda P.R. Galle M. Ducreux T.Y. Kim M. Kudo V. Breder P. Merle A.O. Kaseb D. Li W. Verret D.Z. Xu S. Hernandez J. Liu C. Huang S. Mulla Y. Wang H.Y. Lim A.X. Zhu A.L. Cheng IMbrave150 investigators. atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma N. Engl. J. Med. 382 20 2020 1894 1905 May 14 Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.Y., Kudo M., Breder V., Merle P., Kaseb A.O., Li D., Verret W., Xu D.Z., Hernandez S., Liu J., Huang C., Mulla S., Wang Y., Lim H.Y., Zhu A.X., Cheng A.L.; IMbrave150 investigators. atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med.. 2020 May 14;382(20):1894\u20131905. [54] R.S. Herbst J.C. Soria M. Kowanetz G.D. Fine O. Hamid M.S. Gordon J.A. Sosman D.F. McDermott J.D. Powderly S.N. Gettinger H.E. Kohrt L. Horn D.P. Lawrence S. Rost M. Leabman Y. Xiao A. Mokatrin H. Koeppen P.S. Hegde I. Mellman D.S. Chen F.S. Hodi Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 7528 2014 563 567 Nov 27 Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., Kohrt H.E., Horn L., Lawrence D.P., Rost S., Leabman M., Xiao Y., Mokatrin A., Koeppen H., Hegde P.S., Mellman I., Chen D.S., Hodi F.S. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563\u20137.", "scopus-id": "85144796715", "pubmed-id": "36509402", "coredata": {"eid": "1-s2.0-S1742706122008066", "dc:description": "Transarterial chemoembolization (TACE) is an image-guided locoregional therapy used for the treatment of patients with primary hepatocellular carcinoma (HCC). However, conventional TACE formulations such as epirubicin-lipiodol emulsion are rapidly dissociated due to the instability of the emulsion, resulting in insufficient local drug concentrations in the target tumor. To overcome these limitations, we used biodegradable Idarubicin loaded microspheres (BILMs), which were prepared from gelatin and carrageenan and could be loaded with Idarubicin (IDA-MS). The morphology and the ability to load and release IDA of BILMs were characterized in vitro. We evaluated tumor changes and side effects after TACE treatment with IDA-MS in VX2 rabbit and C57BL/6 mice HCC models. In addition, the effect of IDA-MS on the tumor immune microenvironment of HCC tumors was elucidated via mass spectrometry and immunohistochemistry. Result showed that IDA-MS was developed as a new TACE formulation to overcome the poor delivery of drugs due to rapid elimination of the anticancer drug into the systemic circulation. We demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment. Statement of significance Conventional transarterial chemoembolization (TACE) formulations are rapidly dissociated due to the instability of the emulsion, resulting in insufficient local drug concentrations in hepatocellular carcinoma (HCC). To overcome these limitations, we used biodegradable microspheres called BILMs, which could be loaded with Idarubicin (IDA-MS). We demonstrated in rabbits and mice HCC models that TACE with IDA-MS resulted in significant tumor shrinkage and no more severe adverse events than those observed in the IDA group. TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8+ T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment.", "openArchiveArticle": "false", "prism:coverDate": "2023-02-28", "openaccessUserLicense": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/article/pii/S1742706122008066", "dc:creator": [{"@_fa": "true", "$": "Zheng, Zhiying"}, {"@_fa": "true", "$": "Ma, Mingxi"}, {"@_fa": "true", "$": "Han, Xiuping"}, {"@_fa": "true", "$": "Li, Xiao"}, {"@_fa": "true", "$": "Huang, Jinxin"}, {"@_fa": "true", "$": "Zhao, Yuetong"}, {"@_fa": "true", "$": "Liu, Hanyuan"}, {"@_fa": "true", "$": "Kang, Junwei"}, {"@_fa": "true", "$": "Kong, Xiangyi"}, {"@_fa": "true", "$": "Sun, Guoqiang"}, {"@_fa": "true", "$": "Sun, Guangshun"}, {"@_fa": "true", "$": "Kong, Jie"}, {"@_fa": "true", "$": "Tang, Weiwei"}, {"@_fa": "true", "$": "Shao, Guoqiang"}, {"@_fa": "true", "$": "Xiong, Fei"}, {"@_fa": "true", "$": "Song, Jinhua"}], "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/article/pii/S1742706122008066"}, {"@_fa": "true", "@rel": "scidir", "@href": "https://www.sciencedirect.com/science/article/pii/S1742706122008066"}], "dc:format": "application/json", "openaccessType": "Full", "pii": "S1742-7061(22)00806-6", "prism:volume": "157", "prism:publisher": "The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc.", "dc:title": "Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma", "prism:copyright": "\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc.", "openaccess": "1", "prism:issn": "17427061", "dcterms:subject": [{"@_fa": "true", "$": "Idarubicin"}, {"@_fa": "true", "$": "Hepatocellular carcinoma"}, {"@_fa": "true", "$": "Transcatheter arterial chemoembolization"}, {"@_fa": "true", "$": "Biodegradable microspheres"}, {"@_fa": "true", "$": "Immune"}, {"@_fa": "true", "$": "PD-L1"}, {"@_fa": "true", "$": "PD1"}], "openaccessArticle": "true", "prism:publicationName": "Acta Biomaterialia", "openaccessSponsorType": "Author", "prism:pageRange": "337-351", "prism:endingPage": "351", "pubType": "fla", "prism:coverDisplayDate": "February 2023", "prism:doi": "10.1016/j.actbio.2022.12.004", "prism:startingPage": "337", "dc:identifier": "doi:10.1016/j.actbio.2022.12.004", "openaccessSponsorName": null}, "objects": {"object": [{"@category": "standard", "@height": "907", "@width": "565", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr1.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-DOWNSAMPLED", "@size": "73106", "@ref": "gr1", "@mimetype": "image/jpeg"}, {"@category": "standard", "@height": "941", "@width": "565", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr2.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-DOWNSAMPLED", "@size": "114154", "@ref": "gr2", "@mimetype": "image/jpeg"}, {"@category": "standard", "@height": "969", "@width": "602", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr3.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-DOWNSAMPLED", "@size": "253017", "@ref": "gr3", "@mimetype": "image/jpeg"}, {"@category": "standard", "@height": "913", "@width": "640", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr4.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-DOWNSAMPLED", "@size": "118799", "@ref": "gr4", "@mimetype": "image/jpeg"}, {"@category": "standard", "@height": "940", "@width": "572", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr5.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-DOWNSAMPLED", "@size": "296693", "@ref": "gr5", "@mimetype": "image/jpeg"}, {"@category": "standard", "@height": "987", "@width": "621", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr6.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-DOWNSAMPLED", "@size": "223284", "@ref": "gr6", "@mimetype": "image/jpeg"}, {"@category": "standard", "@height": "941", "@width": "534", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr7.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-DOWNSAMPLED", "@size": "236681", "@ref": "gr7", "@mimetype": "image/jpeg"}, {"@category": "standard", "@height": "993", "@width": "378", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr8.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-DOWNSAMPLED", "@size": "130310", "@ref": "gr8", "@mimetype": "image/jpeg"}, {"@category": "standard", "@height": "200", "@width": "274", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-ga1.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-DOWNSAMPLED", "@size": "27399", "@ref": "ga1", "@mimetype": "image/jpeg"}, {"@category": "thumbnail", "@height": "164", "@width": "102", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr1.sml?httpAccept=%2A%2F%2A", "@multimediatype": "GIF image file", "@type": "IMAGE-THUMBNAIL", "@size": "5048", "@ref": "gr1", "@mimetype": "image/gif"}, {"@category": "thumbnail", "@height": "163", "@width": "98", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr2.sml?httpAccept=%2A%2F%2A", "@multimediatype": "GIF image file", "@type": "IMAGE-THUMBNAIL", "@size": "8543", "@ref": "gr2", "@mimetype": "image/gif"}, {"@category": "thumbnail", "@height": "163", "@width": "101", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr3.sml?httpAccept=%2A%2F%2A", "@multimediatype": "GIF image file", "@type": "IMAGE-THUMBNAIL", "@size": "12484", "@ref": "gr3", "@mimetype": "image/gif"}, {"@category": "thumbnail", "@height": "164", "@width": "115", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr4.sml?httpAccept=%2A%2F%2A", "@multimediatype": "GIF image file", "@type": "IMAGE-THUMBNAIL", "@size": "7980", "@ref": "gr4", "@mimetype": "image/gif"}, {"@category": "thumbnail", "@height": "163", "@width": "99", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr5.sml?httpAccept=%2A%2F%2A", "@multimediatype": "GIF image file", "@type": "IMAGE-THUMBNAIL", "@size": "12188", "@ref": "gr5", "@mimetype": "image/gif"}, {"@category": "thumbnail", "@height": "164", "@width": "103", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr6.sml?httpAccept=%2A%2F%2A", "@multimediatype": "GIF image file", "@type": "IMAGE-THUMBNAIL", "@size": "8959", "@ref": "gr6", "@mimetype": "image/gif"}, {"@category": "thumbnail", "@height": "164", "@width": "93", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr7.sml?httpAccept=%2A%2F%2A", "@multimediatype": "GIF image file", "@type": "IMAGE-THUMBNAIL", "@size": "11631", "@ref": "gr7", "@mimetype": "image/gif"}, {"@category": "thumbnail", "@height": "163", "@width": "62", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr8.sml?httpAccept=%2A%2F%2A", "@multimediatype": "GIF image file", "@type": "IMAGE-THUMBNAIL", "@size": "5724", "@ref": "gr8", "@mimetype": "image/gif"}, {"@category": "thumbnail", "@height": "160", "@width": "219", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-ga1.sml?httpAccept=%2A%2F%2A", "@multimediatype": "GIF image file", "@type": "IMAGE-THUMBNAIL", "@size": "15085", "@ref": "ga1", "@mimetype": "image/gif"}, {"@category": "high", "@height": "4015", "@width": "2500", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr1_lrg.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-HIGH-RES", "@size": "547381", "@ref": "gr1", "@mimetype": "image/jpeg"}, {"@category": "high", "@height": "4164", "@width": "2500", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr2_lrg.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-HIGH-RES", "@size": "924932", "@ref": "gr2", "@mimetype": "image/jpeg"}, {"@category": "high", "@height": "4295", "@width": "2667", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr3_lrg.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-HIGH-RES", "@size": "2386002", "@ref": "gr3", "@mimetype": "image/jpeg"}, {"@category": "high", "@height": "4040", "@width": "2833", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr4_lrg.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-HIGH-RES", "@size": "938992", "@ref": "gr4", "@mimetype": "image/jpeg"}, {"@category": "high", "@height": "4165", "@width": "2534", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr5_lrg.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-HIGH-RES", "@size": "3126291", "@ref": "gr5", "@mimetype": "image/jpeg"}, {"@category": "high", "@height": "4372", "@width": "2750", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr6_lrg.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-HIGH-RES", "@size": "2102340", "@ref": "gr6", "@mimetype": "image/jpeg"}, {"@category": "high", "@height": "4167", "@width": "2365", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr7_lrg.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-HIGH-RES", "@size": "2734602", "@ref": "gr7", "@mimetype": "image/jpeg"}, {"@category": "high", "@height": "4398", "@width": "1675", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-gr8_lrg.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-HIGH-RES", "@size": "1288439", "@ref": "gr8", "@mimetype": "image/jpeg"}, {"@category": "high", "@height": "886", "@width": "1215", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-ga1_lrg.jpg?httpAccept=%2A%2F%2A", "@multimediatype": "JPEG image file", "@type": "IMAGE-HIGH-RES", "@size": "204816", "@ref": "ga1", "@mimetype": "image/jpeg"}, {"@category": "thumbnail", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-si1.svg?httpAccept=%2A%2F%2A", "@multimediatype": "Scalable Vector Graphics file", "@type": "ALTIMG", "@size": "7895", "@ref": "si1", "@mimetype": "image/svg+xml"}, {"@category": "thumbnail", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-si2.svg?httpAccept=%2A%2F%2A", "@multimediatype": "Scalable Vector Graphics file", "@type": "ALTIMG", "@size": "6991", "@ref": "si2", "@mimetype": "image/svg+xml"}, {"@category": "thumbnail", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-si6.svg?httpAccept=%2A%2F%2A", "@multimediatype": "Scalable Vector Graphics file", "@type": "ALTIMG", "@size": "18461", "@ref": "si6", "@mimetype": "image/svg+xml"}, {"@category": "thumbnail", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-si3.svg?httpAccept=%2A%2F%2A", "@multimediatype": "Scalable Vector Graphics file", "@type": "ALTIMG", "@size": "26294", "@ref": "si3", "@mimetype": "image/svg+xml"}, {"@category": "thumbnail", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-si4.svg?httpAccept=%2A%2F%2A", "@multimediatype": "Scalable Vector Graphics file", "@type": "ALTIMG", "@size": "23912", "@ref": "si4", "@mimetype": "image/svg+xml"}, {"@category": "thumbnail", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-si5.svg?httpAccept=%2A%2F%2A", "@multimediatype": "Scalable Vector Graphics file", "@type": "ALTIMG", "@size": "36625", "@ref": "si5", "@mimetype": "image/svg+xml"}, {"@category": "standard", "@_fa": "true", "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1742706122008066-am.pdf?httpAccept=%2A%2F%2A", "@multimediatype": "Acrobat PDF file", "@type": "AAM-PDF", "@size": "4946231", "@ref": "am", "@mimetype": "application/pdf"}]}, "link": {"@rel": "abstract", "@href": "https://api.elsevier.com/content/abstract/scopus_id/85144796715"}}